(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Congenital Hyperinsulinism pipeline constitutes 4+ key companies continuously working towards developing 6+ Congenital Hyperinsulinism treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Congenital Hyperinsulinism Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Congenital Hyperinsulinism Market.
The Congenital Hyperinsulinism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Congenital Hyperinsulinism Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Congenital Hyperinsulinism treatment therapies with a considerable amount of success over the years.
-
Congenital Hyperinsulinism companies working in the treatment market are Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others, are developing therapies for the Congenital Hyperinsulinism treatment
-
Emerging Congenital Hyperinsulinism therapies in the different phases of clinical trials are- CRN-04777, HM 15136, RZ358, Dasiglucagon, and others are expected to have a significant impact on the Congenital Hyperinsulinism market in the coming years.
-
In July 2023, Zealand Pharma has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its treatment dasiglucagon, intended for pediatric patients aged seven days or older with congenital hyperinsulinism (CHI).
-
In June 2023, Zealand Pharma has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for dasiglucagon. This application aims to seek approval for the use of dasiglucagon in preventing and treating low blood sugar (hypoglycemia) in pediatric patients aged 7 days or older diagnosed with congenital hyperinsulinism. The NDA submission is supported by data from two critical Phase 3 trials, along with interim findings from an ongoing long-term extension trial.
-
In September 2022, Zealand Pharma has declared a global license and development collaboration with Novo Nordisk A/S for the commercialization of ZEGALOGUE (dasiglucagon) for injection. As part of this agreement, Zealand will receive an initial payment of DKK 25 million and stands to gain up to DKK 45 million in upcoming development, regulatory, and manufacturing-related milestones.
Congenital Hyperinsulinism Overview
Congenital Hyperinsulinism (CHI) is a rare genetic disorder characterized by the excessive production and secretion of insulin by the beta cells in the pancreas. Insulin is a hormone responsible for regulating blood sugar levels by promoting the uptake of glucose into cells. In individuals with congenital hyperinsulinism, there is an abnormality in the regulation of insulin secretion, leading to hypoglycemia (low blood sugar).
Get a Free Sample PDF Report to know more about Congenital Hyperinsulinism Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/congenital-hyperinsulinism-pipeline-insight
Emerging Congenital Hyperinsulinism Drugs Under Different Phases of Clinical Development Include:
-
CRN-04777: Crinetics Pharmaceuticals
-
HM 15136: Hanmi Pharmaceutical
-
RZ358: Rezolute
-
Dasiglucagon: Zealand Pharma
Congenital Hyperinsulinism Route of Administration
Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Congenital Hyperinsulinism Molecule Type
Congenital Hyperinsulinism Products have been categorized under various Molecule types, such as
Congenital Hyperinsulinism Pipeline Therapeutics Assessment
-
Congenital Hyperinsulinism Assessment by Product Type
-
Congenital Hyperinsulinism By Stage and Product Type
-
Congenital Hyperinsulinism Assessment by Route of Administration
-
Congenital Hyperinsulinism By Stage and Route of Administration
-
Congenital Hyperinsulinism Assessment by Molecule Type
-
Congenital Hyperinsulinism by Stage and Molecule Type
DelveInsight’s Congenital Hyperinsulinism Report covers around 6+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Congenital Hyperinsulinism product details are provided in the report. Download the Congenital Hyperinsulinism pipeline report to learn more about the emerging Congenital Hyperinsulinism therapies
Some of the key companies in the Congenital Hyperinsulinism Therapeutics Market include:
Key companies developing therapies for Congenital Hyperinsulinism are – Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Crinetics Pharmaceuticals, and others.
Congenital Hyperinsulinism Pipeline Analysis:
The Congenital Hyperinsulinism pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Congenital Hyperinsulinism with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Congenital Hyperinsulinism Treatment.
-
Congenital Hyperinsulinism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Congenital Hyperinsulinism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Congenital Hyperinsulinism market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Congenital Hyperinsulinism drugs and therapies
Congenital Hyperinsulinism Pipeline Market Drivers
Congenital Hyperinsulinism Pipeline Market Barriers
Scope of Congenital Hyperinsulinism Pipeline Drug Insight
-
Coverage: Global
-
Key Congenital Hyperinsulinism Companies: Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others
-
Key Congenital Hyperinsulinism Therapies: CRN-04777, HM 15136, RZ358, Dasiglucagon, and others
-
Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies
-
Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers
Request for Sample PDF Report for Congenital Hyperinsulinism Pipeline Assessment and clinical trials
Table of Contents
1. Congenital Hyperinsulinism Report Introduction
2. Congenital Hyperinsulinism Executive Summary
3. Congenital Hyperinsulinism Overview
4. Congenital Hyperinsulinism- Analytical Perspective In-depth Commercial Assessment
5. Congenital Hyperinsulinism Pipeline Therapeutics
6. Congenital Hyperinsulinism Late Stage Products (Phase II/III)
7. Congenital Hyperinsulinism Mid Stage Products (Phase II)
8. Congenital Hyperinsulinism Early Stage Products (Phase I)
9. Congenital Hyperinsulinism Preclinical Stage Products
10. Congenital Hyperinsulinism Therapeutics Assessment
11. Congenital Hyperinsulinism Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Congenital Hyperinsulinism Key Companies
14. Congenital Hyperinsulinism Key Products
15. Congenital Hyperinsulinism Unmet Needs
16 . Congenital Hyperinsulinism Market Drivers and Barriers
17. Congenital Hyperinsulinism Future Perspectives and Conclusion
18. Congenital Hyperinsulinism Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Congenital Hyperinsulinism Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials by DelveInsight | Zealand Pharma, Rezolute, Hanmi Pharma, Crinetics Pharma
